Quadria Capital
VC Fund
Singapore, Singapore
Quadria Capital is a healthcare focused private equity fund that invests in the high growth healthcare sector of some of the world's fastest growing economies in South Asia and Southeast Asia. Quadria Capital aims to generate significant financial returns for its investors by leveraging the team's operational and transactional experiencein healthcare to invest in high quality and scalable healthcare organizations to address the critical and undersupplied healthcare needs in the region.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 67%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Quadria Capital invests in
Stages Quadria Capital invests in
Countries Quadria Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Private Equity
- $13M–$100M
Investment Focus
Industry
- Health Care 14 (52%)
- Medical 7 (26%)
- Manufacturing 6 (22%)
- Hospital 5 (19%)
- Pharmaceutical 3 (11%)
Stage
- Private Equity 17 (63%)
- Funding Round 2 (7%)
- Series A 1 (4%)
- Series C 1 (4%)
- Series F 1 (4%)
Country
- India 15 (56%)
- Vietnam 2 (7%)
- Indonesia 2 (7%)
- Malaysia 1 (4%)
- United States 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amit Varma
Co-founder & Managing Partner
|
Co-founder & Managing Partner | Total investments: 8 | Find email | |
Sunil Thakur
Director
|
Director | Total investments: 6 | Find email | |
Abrar Mir
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aragen Life Sciences
|
GVK Biosciences (GVK BIO) is one of Asia’s leading Discovery Research and Development organizations. GVK BIO provides a broad spectrum of services, across the R&D and manufacturing value chain with a focus on speed and quality. GVK BIO capabilities include Integrated Programs, Discovery Services, Clinical Development, Contract Manufacturing,Formulations and Informatics.GVK BIO has over a decade of rich experience in providing breakthrough drug discovery and development services. Their team of scientists, backed by well-laid processes and cutting edge technologies, enable customers to achieve unmatched results.GVK BIO’s 2400 employees serve a diverse and global customer base of more than 300 satisfied customers. They have consistently exceeded their customers’ expectations in terms of quality, speed and affordability. Precisely why, their clientele who are among the global top 10 in the fields of Pharmaceutical, Agrochemical, Electronics, Biotechnology and Academics entrust us with their research challenges. | $100M / Private Equity / Jan 13, 2025 | |
NephroPlus
|
NephroPlus operates a network of dialysis centers with the goal of providing quality dialysis at low pricing through the use of standardized protocols, constant training, and focused innovation. The company's network provides dialysis, kidney stone treatment, arteriovenous fistula procedures, and other treatments linked to renal and urologicaldisorders. | $12M / Series F / May 03, 2024 | |
MediBuddy
|
MediBuddy is a digital healthcare platform for an inpatient hospitalization, outpatient services, and corporate wellness benefits.MediBuddy is the award-winning technology platform from Medi Assist that transforms the health insurance industry at the very core. MediBuddy, with its diverse offerings for various stakeholders of the health benefitsindustry, makes the process of discovering, accessing, utilizing, and monitoring health benefits seamless, real-time, and virtually paperless. The company was founded in 2000 and based in Bangalore, Karnataka, India. | $18M / Aug 30, 2023 | |
|
MediBuddy
|
MediBuddy is a digital healthcare platform for an inpatient hospitalization, outpatient services, and corporate wellness benefits.MediBuddy is the award-winning technology platform from Medi Assist that transforms the health insurance industry at the very core. MediBuddy, with its diverse offerings for various stakeholders of the health benefitsindustry, makes the process of discovering, accessing, utilizing, and monitoring health benefits seamless, real-time, and virtually paperless. The company was founded in 2000 and based in Bangalore, Karnataka, India. | $18M / Aug 30, 2023 | |
Maxivision Super Speciality Eye Hospitals
|
Maxivision Super Speciality Eye Hospitals is eye care hospital | $73.2M / Private Equity / Jul 12, 2023 | |
|
MediBuddy
|
MediBuddy is a digital healthcare platform for an inpatient hospitalization, outpatient services, and corporate wellness benefits.MediBuddy is the award-winning technology platform from Medi Assist that transforms the health insurance industry at the very core. MediBuddy, with its diverse offerings for various stakeholders of the health benefitsindustry, makes the process of discovering, accessing, utilizing, and monitoring health benefits seamless, real-time, and virtually paperless. The company was founded in 2000 and based in Bangalore, Karnataka, India. | $125M / Series C / Feb 22, 2022 | |
|
MediBuddy
|
MediBuddy is a digital healthcare platform for an inpatient hospitalization, outpatient services, and corporate wellness benefits.MediBuddy is the award-winning technology platform from Medi Assist that transforms the health insurance industry at the very core. MediBuddy, with its diverse offerings for various stakeholders of the health benefitsindustry, makes the process of discovering, accessing, utilizing, and monitoring health benefits seamless, real-time, and virtually paperless. The company was founded in 2000 and based in Bangalore, Karnataka, India. | $125M / Series C / Feb 22, 2022 | |
Concung
|
Concung Corporation is an extremely fast growing technology company for mom & baby products with one new store opened every day with the annual growth rate of 70%. By the end of 2022, the revenue is more than $500 million USD with 1,000 stores & 10 flagship hubs. Concung has more than millions of e-commerce users. With the vision ofproviding good quality products for moms, babies and kids from newborn to 12 year old. Con Cung addressable market size is more than 50 millions of population. It positions to cover all products and services for this market. As a tech company, Con Cung develops strong IT infrastructure for its e-commerce, hub/retail network, supply chain and operation/sales automation. Concung also invests into Research and Development in order to manufacture and provide products that are suitable and superior to the local market in terms of quality and pricing. All of the products must follow strict safety standards.With its extremely efficient management capability, the company is highly profitable with minimal capital investment. Con Cung maintains profitable even at the first year of establishment and shows to be a resilient business even during the Covid-19 pandemics. Concung Corporation is dynamic and vibrant. The management team are mostly in the age of 30s. Many of them are now holding the director positions with highly competitive benefit packages. The corporate culture is transparent, result oriented and fast decision making. The company nurtures and supports the creativity and originality of ideas. The working environment allows talents to prosper and promote quickly. | $90M / Private Equity / Jan 18, 2022 | |
|
Concung
|
Concung Corporation is an extremely fast growing technology company for mom & baby products with one new store opened every day with the annual growth rate of 70%. By the end of 2022, the revenue is more than $500 million USD with 1,000 stores & 10 flagship hubs. Concung has more than millions of e-commerce users. With the vision ofproviding good quality products for moms, babies and kids from newborn to 12 year old. Con Cung addressable market size is more than 50 millions of population. It positions to cover all products and services for this market. As a tech company, Con Cung develops strong IT infrastructure for its e-commerce, hub/retail network, supply chain and operation/sales automation. Concung also invests into Research and Development in order to manufacture and provide products that are suitable and superior to the local market in terms of quality and pricing. All of the products must follow strict safety standards.With its extremely efficient management capability, the company is highly profitable with minimal capital investment. Con Cung maintains profitable even at the first year of establishment and shows to be a resilient business even during the Covid-19 pandemics. Concung Corporation is dynamic and vibrant. The management team are mostly in the age of 30s. Many of them are now holding the director positions with highly competitive benefit packages. The corporate culture is transparent, result oriented and fast decision making. The company nurtures and supports the creativity and originality of ideas. The working environment allows talents to prosper and promote quickly. | $90M / Private Equity / Jan 18, 2022 | |
Encube Ethicals
|
Encube Ethicals a contract development and manufacturing organization, specializes in topical semisolid formulations. | Private Equity / Jun 28, 2021 | |
| See all 27 investments → | |||
Co-Investors
Lightrock india (Aspada)
4 deals together
TEAMFund
4 deals together
Alteria Capital
2 deals together
Bessemer Venture Partners
2 deals together
FinSight Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Quadria Capital invest in?
Quadria Capital invests primarily in Health Care, Medical and Manufacturing startups, most often at Private Equity and Funding Round stage. Most of the 27 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Quadria Capital's check size?
Quadria Capital typically joins rounds of $13M–$100M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Quadria Capital participates in.
How do I contact Quadria Capital?
Public channels for Quadria Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Quadria Capital?
The team at Quadria Capital includes Amit Varma (Co-founder & Managing Partner), Sunil Thakur (Director) and Abrar Mir (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
